Miguel Bronchud, Veteran Cancer Clinician and Researcher and Co-Founder of Regenerative Medicine Solutions, shared on LinkedIn:
“Clear cell cancers are not good news. Ovarian ‘clear cell cancer’ is a rare and biologically distinct and clinically aggressive ovarian cancer subtype, representing approximately 20–25% of ovarian cancers in the Asia-Pacific region: reports Department of Haematology-Oncology, National University Cancer Institute Singapore, 119228, Singapore.
Its genomic landscape is characterised by a predominantly homologous-recombination deficiency-negative phenotype, with recurrent alterations in ARID1A(40–50%) and PIK3CA (30–40%), suggesting a biology driven by epigenetic dysregulation or oncogenic signalling, rather than genomic instability.
Prospective studies dedicated to ovarian clear cell cancer are scarce, and no biomarker-informed therapeutic strategy has yet successfully translated into an effective, genomically matched approach.
Rare cancers are usually defined as an incidence of <6/100,000 persons per year. Gynecological oncology is characterized by a paradoxical high prevalence of rare cancer subtypes, especially in ovarian tumors.
Ovarian germ cell tumors, clear cell ovarian cancer and gestational trophoblastic disease encompass this set of gynecologic tumors.
The WHO classification distinguishes epithelial cell tumors (85% of malignant tumors) from non-epithelial tumors, sex cord stromal tumors (8% of malignant tumors), and germ cell tumors (6% of malignant tumors). The current treatment for these tumors is similar to that for ovarian cancer but advancing quickly to incorporate targeted therapy.
Gestational trophoblastic tumors are usually curable, even when widely metastatic disease is present. Ovarian clear-cell carcinoma (OCCC) remains a challenging disease characterized by intrinsic chemoresistance and distinct molecular features. A more biologically aligned treatment strategy has emerged.
See also: Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial- Lancet Oncol. 2026; published online Nov 10.
Clear cell tumors are characterized by cells with large clear cytoplasm due to lipids and glycogen accumulation – and are usually associated with resistance to chemotherapy. They are usually associated with kidney tumors but can also be endometrial.
Clear cell carcinoma represents less than 4% of all cases of endometrial carcinoma and commonly occurs in older black women.”
Title: Genomically matched targeted therapy for ovarian clear cell carcinoma
Authors: Natalie Y L Ngoi.
Title: Risovalisib for PIK3CA-mutated recurrent or persistent ovarian clear cell carcinoma: a single-arm, multicentre, phase 2 trial
Authors: Jiajia Li, Kan Yonemori, Kaoru Niimi, Satoshi Nakagawa, Kosuke Yoshihara, Shogo Shigeta, Jianqing Zhu, Hui Qiu, Jie Tang, Hidemichi Watari, Tatsuyuki Chiyoda, Shoji Nagao, Zhiqing Liang, Yuanguang Meng, Huimei Zhou, Ruifang An, Aikou Okamoto, Shin Nishio, Kazuhiro Takehara, Junzo Hamanishi, Shuzhong Yao, Fengxia Xue, Ge Lou, Hongming Pan, Wenjun Cheng, Rutie Yin, Wei Duan, Muneaki Shimada, Yixiang Zhang, Yibin Wang, Fugen Li, Juan Chen, Chenxian Dai, Chao Lv, Jihong Liu, Xiaohua Wu.
You can also read: